Literature DB >> 18383875

Alpha 1 antichymotrypsin genotype is associated with increased risk of prostate carcinoma and PSA levels.

Federico Licastro1, Alessandro Bertaccini, Elisa Porcellini, Martina Chiappelli, Remigio Pernetti, Francesco Sanguedolce, Debora Marchiori, Giuseppe Martorana.   

Abstract

BACKGROUND: Prostate cancer (PCa) is the most common non-skin cancer among men in Western countries. Inflammation appears to be involved in the pathogenesis of PCa. Recent studies have shown that many inflammatory genes are associated with the risk of PCa. Alpha 1 antichymotrypsin (ACT) is an acute phase protein and it is part of the circulating prostate specific antigen (PSA). PATIENTS AND METHODS: Allele and genotype frequencies of a promoter single nucleotide polymorphism (SNP) in ACT gene were investigated in patients with benign prostate hypertrophy (BHP) or PCa and controls.
RESULTS: The G allele was more represented in PCa patients (odds ratio = 2.349). The PSA levels and prostatic volume did not correlate with the ACT genotype. However, stratifying subjects by age, a correlation of PSA levels and the GG genotype in young PCa patients was found.
CONCLUSION: Carriers of the ACT G allele are at risk of developing PCa and genotyping healthy subjects could be a new approach for early prevention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18383875

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

Review 1.  Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments.

Authors:  C R Balistreri; G Candore; D Lio; G Carruba
Journal:  Cancer Gene Ther       Date:  2014-01-10       Impact factor: 5.987

Review 2.  Prostate cancer and inflammation: the evidence.

Authors:  Karen S Sfanos; Angelo M De Marzo
Journal:  Histopathology       Date:  2012-01       Impact factor: 5.087

Review 3.  Systematic review and meta-analysis of candidate gene association studies of lower urinary tract symptoms in men.

Authors:  Rufus Cartwright; Altaf Mangera; Kari A O Tikkinen; Prabhakar Rajan; Jori Pesonen; Anna C Kirby; Ganesh Thiagamoorthy; Chris Ambrose; Juan Gonzalez-Maffe; Phillip R Bennett; Tom Palmer; Andrew Walley; Marjo-Riitta Järvelin; Vik Khullar; Chris Chapple
Journal:  Eur Urol       Date:  2014-01-22       Impact factor: 20.096

Review 4.  Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review.

Authors:  Alessandro Sciarra; Alessandro Gentilucci; Stefano Salciccia; Federico Pierella; Flavio Del Bianco; Vincenzo Gentile; Ida Silvestri; Susanna Cattarino
Journal:  J Inflamm (Lond)       Date:  2016-11-25       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.